Resistance to antibody–drug conjugates: A review

Antibody-drug conjugates (ADCs) are antitumor drugs composed of monoclonal antibodies and cytotoxic payload covalently coupled by a linker. Currently, 15 ADCs have been clinically approved worldwide. More than 100 clinical trials at different phases are underway to investigate the newly developed ADCs. ADCs represent one of the fastest growing classes of targeted antitumor drugs in oncology drug development. It takes advantage of the specific targeting of tumor-specific antigen by antibodies to deliver cytotoxic chemotherapeutic drugs precisely to tumor cells, thereby producing promising antitumor efficacy and favorable adverse effect profiles. However, emergence of drug resistance has severely hindered the…

• NN
  National Natural Science Foundation of China

  Awards: 82073882, U21A20421
• GS
  Guangzhou Science and Technology Program key projects

  Award: 2023B03J0029
• SP
  Special Project for Research and Development in Key areas of Guangdong Province

  Award: 2023B1111020005
• BA
  Basic and Applied Basic Research Foundation of Guangdong Province

  Award: 2023B1515130009